Supervisory Board

Kiadis Pharma’s Supervisory Board supervises and advises Management on the general course of affairs of the Company and its affiliated enterprises.

Mark Wegter

Chairman of the Supervisory Board

Mark Wegter joined our Board in 2001 as a representative of LSP, where he is a Managing Partner. He has been the company’s Chairman since. Prior to joining LSP, Mark worked as a Senior Analyst at ING Corporate and Investment Banking. Mark brings 20 years of hands-on finance, investment and board experience in the biotechnology sector to the Kiadis team, playing an active role in its growth and strategic direction. For the past 10 years, he has focused his professional attention to investing in publicly listed biotech companies that fall within the small- and mid-cap segment, building a track record of taking  positions in undervalued companies and holding on to them long term. Mark holds a Master’s degree in Business Economics from the Erasmus University of Rotterdam.

Dr. Robert Soiffer

Supervisory Board Member

Dr. Soiffer became a member of the Supervisory Board on June 28, 2016. Dr. Soiffer is currently a Professor at Harvard University Medical School, Chief of the Division of Hematologic Malignancies at the Dana-Farber Cancer Institute, or DFCI and Codirector of the Adult Stem Cell Transplantation Program at the DFCI. Dr. Soiffer joined the DFCI in 1988, after completing a medical oncology fellowship. Dr. Soiffer sits on the board of the U.S. National Marrow Donor Program’s Be the Match Registry, or NMDP and on the Massachusetts Board of the Leukemia and Lymphoma Society. Dr. Soiffer is also Chairman of the Advisory Committee for International Blood and Marrow Research. From May 7, 2014 through May 7, 2015, Dr. Soiffer served as a member of Kiadis Pharma Netherlands B.V.’s Scientific Advisory Board while it was conducting clinical trials in Canada and Europe.

Mark Wegter

Chairman of the Supervisory Board

Dr. Robert Soiffer

Supervisory Board Member